乳腺癌患者赫赛汀相关心脏毒性机制及处理

中国临床药理学与治疗学 ›› 2011, Vol. 16 ›› Issue (9): 1077-1080.

• 综述与讲座 • 上一篇

乳腺癌患者赫赛汀相关心脏毒性机制及处理

盛李明, 杜向慧

浙江省肿瘤医院放疗科,杭州 310022,浙江

收稿日期:2011-07-14 修回日期:2011-08-13 出版日期:2011-09-26 发布日期:2011-10-11
通讯作者: 杜向慧,女,主任医师,从事胸部肿瘤放疗工作。Tel: 0571-88122081 E-mail: vip20112012@163.com
作者简介:盛李明,男,医学硕士,住院医师,从事胸部肿瘤放疗工作。Tel: 0571-88122081 E-mail: m05shengliming@zju.edu.cn
基金资助:
浙江省教育厅2010年度科研计划项目(Y201019160)

Trastuzumab associated cardiac adverse effects in breast cancer

SHENG Li-ming, DU Xiang-hui

Department of Radiotherapy, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang, China

Received:2011-07-14 Revised:2011-08-13 Online:2011-09-26 Published:2011-10-11

摘要/Abstract

摘要： 近几年来赫赛汀作为针对人表皮生长因子受体2(human epidermal growth factor receptor-2,HER2)的靶向药物被广泛应用于早期、晚期乳腺癌患者,赫赛汀相关心脏毒性虽然发生率低,但对患者生命具有一定的潜在危险。无症状左室射血分数(LVEF)下降是最常见的心脏毒性事件,通常情况下是可控制和可逆的。赫赛汀相关心脏毒性发生与患者年龄、既往高血压病史和蒽环类为基础的化疗有关。赫赛汀治疗期间需要进行严密的心脏功能监测。

关键词: 乳腺癌, 赫赛汀, 心脏毒性, 靶向治疗

Abstract: Trastuzumab has been used widely for the treatment of women with human epidermal growth factor receptor-2(HER2) overexpressing breast cancer in the early and advanced disease. However, cardiac toxicity has emerged as a rare but potentially serious risk that limits its therapeutic potential in a subset of women.Asymptomatic decreasing left ventricular ejection fraction (LVEF) was a common complication and generally reversible and manageable.The increasing risk of trastuzumab-induced cardiac toxicity may be influenced by factors such as age, hypertension and the use of anthracyclines-based chemotherapy.Rigorous cardiac monitoring should be performed for all patients receiving trastuzumab currently in clinic.

Key words: Breast cancer, Trastuzumab, Cardiac toxicity, Targeted therapy

中图分类号:

R737.9

盛李明, 杜向慧. 乳腺癌患者赫赛汀相关心脏毒性机制及处理[J]. 中国临床药理学与治疗学, 2011, 16(9): 1077-1080.

SHENG Li-ming, DU Xiang-hui. Trastuzumab associated cardiac adverse effects in breast cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(9): 1077-1080.

参考文献

[1] Cuadros M, Cano C, López FJ, et al. HER2 status in breast cancer: experience of a Spanish National Reference Centre [J]. Clin Transl Oncol, 2011, 13(5): 335-340.
[2] 赵文英, 吴万春. 心理危机干预改善晚期乳腺癌患者生活质量的研究[J]. 中国临床药理学与治疗学, 2010, 15(1): 101-105.
[3] Spielmann M, Roché H, Delozier T, et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial [J]. J Clin Oncol, 2009, 27(36): 6129-6134.
[4] Slamon D, Eiermann W, Robert NPT, et al. BCIRG 006 Phase III Trial Comparing AC→T with AC→TH and with TCH in the adjuvant treatment of HER2-amplified early breast cancer patients: third planned efficacy analysis [J]. Cancer Res, 2009, 29: abstract 62.
[5] Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial [J]. J Clin Oncol, 2008, 26(8): 1231-1238.
[6] Rastogi P, Jeong J, Geyer CE, et al. Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide(AC)→paclitaxel(T) vs. AC→T with trastuzumab(H) [J]. J Clin Oncol, 2007, 25(18S): LBA513.
[7] Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial [J]. J Clin Oncol, 2007, 25(25): 3859-3865.
[8] Chen T, Xu T, Li Y, et al. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis [J]. Cancer Treat Rev, 2011, 37(4): 312-320.
[9] 韦劲松, 李志革, 宋向群, 等. Herceptin联合化疗治疗Her2过度表达的转移性乳腺癌的初步观察[J]. 中国癌症防治杂志, 2010, 2(1): 22-24.
[10] Rohrbach S, Niemann B, Silber RE, et al. Neuregulin receptors erbB2 and erbB4 in failing human myocardium-depressed expression and attenuated activation [J]. Basic Res Cardiol, 2005, 100(3): 240-249.
[11] Chien KR. Herceptin and the heart--a molecular modifier of cardiac failure [J]. N Engl J Med, 2006, 354(8): 789-790.
[12] Bria E, Cuppone F, Milella M, et al. Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues [J]. Expert Opin Biol Ther, 2008, 8(12): 1963-1971.
[13] Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience [J]. J Clin Oncol, 2006, 24(25): 4107-4115.
[14] Pentassuglia L, Graf M, Lane H, et al. Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes [J]. Exp Cell Res, 2009, 315(7): 1302-1312.
[15] Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy [J]. Circulation, 2004, 109(22): 2749-2754.
[16] Morris PG, Chen C, Steingart R, et al. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib [J]. Clin Cancer Res, 2011, 17(10): 3490-3499.
[17] Van Hasselt JG, Boekhout AH, Beijnen JH, et al. Population Pharmacokinetic-Pharmacodynamic Analysis of Trastuzumab-Associated Cardiotoxicity [J]. Clin Pharmacol Ther, 2011, 90(1): 126-132.
[18] Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition [J]. Circulation, 2006, 114(23): 2474-2481.
[19] Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer [J]. N Engl J Med, 2006, 354(8): 809-820.
[20] Christodoulou C, Kostopoulos I, Kalofonos HP, et al. Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group(HeCOG) with biomarker evaluation [J]. Oncology, 2009, 76(4): 275-285.
[21] Chia S, Clemons M, Martin LA, et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial [J]. J Clin Oncol, 2006, 24(18): 2773-2778.
[22] Costa RB, Kurra G, Greenberg L, et al. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer [J]. Ann Oncol, 2010, 21(11): 2153-2160.
[23] Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer [J]. N Engl J Med, 2006, 355(26): 2733-2743.

编辑推荐 0

Metrics

阅读次数

全文

172

HTML			PDF

最新录用	在线预览	正式出版	最新录用	在线预览	正式出版
0	0	0	0	0	172

来源	本网站	其他网站

次数	118	54
比例	69%	31%

摘要

204

最新录用	在线预览	正式出版

0	0	204

	来源	本网站

	次数	204
	比例	100%

乳腺癌患者赫赛汀相关心脏毒性机制及处理

Trastuzumab associated cardiac adverse effects in breast cancer

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐 0

Metrics

本文评价

[1]	何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
[2]	张胡云龙, 朱秀之, 金希, 邵志敏. 腔面型乳腺癌内分泌治疗耐药的机制与治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 854-865.
[3]	付晓玉, 孔德光, 李娟娟. 三阳性乳腺癌的治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 866-875.
[4]	罗师萍, 张捷, 俞育帅, 宋传贵. HER2阳性乳腺癌的靶向治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 876-886.
[5]	向奕玫, 张宁宁, 黄雨昕, 曾晓华. HER2阳性乳腺癌疗效相关生物标志物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 887-897.
[6]	陈柯羽, 黄圆, 王晓稼, 郑亚兵. 抗体偶联药物在乳腺癌中的临床应用与研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 898-909.
[7]	李梦茜, 张克兢, 夏凡. 乳腺癌疫苗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 918-925.
[8]	陈满新, 张丙雨, 戴敏. 冠状动脉内靶向应用重组人尿激酶原联合经皮冠状动脉成形术治疗高负荷血栓急性心肌梗死临床疗效[J]. 中国临床药理学与治疗学, 2023, 28(5): 544-549.
[9]	李艳阳, 王云姣, 吕仕超. 中药注射液防治抗肿瘤药物心脏毒性的效应和机制[J]. 中国临床药理学与治疗学, 2023, 28(5): 572-577.
[10]	王智, 周鑫, 何雪茹, 付裕豪, 荀雪姣, 李颖, 董占军. 哌柏西利治疗乳腺癌的临床研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 205-213.
[11]	王秀, 季麒麟, 裴文俊, 曾颖. 3-溴丙酮酸-胆固醇酯增强乳腺癌细胞对他莫昔芬敏感性研究[J]. 中国临床药理学与治疗学, 2023, 28(10): 1093-1100.
[12]	王琳, 李重阳, 李帅虎, 高盛涵, 徐甜, 李飞. 肺癌中致病融合基因的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(8): 877-885.
[13]	武帅, 杨君, 郑云. 乳腺癌中具有双重功能的miRNA[J]. 中国临床药理学与治疗学, 2022, 27(7): 814-821.
[14]	施经斌, 熊阳. 肿瘤微环境与乳腺癌细胞互作导致肿瘤转移的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(5): 562-574.
[15]	董伟, 黄小英, 谢冰斌, 汤喜兰, 李洪铭, 邱雨美, 赵国巍, 梁新丽. 氧化前胡素对乳腺癌MCF-7/DOX细胞多柔比星耐药的抑制作用[J]. 中国临床药理学与治疗学, 2022, 27(3): 260-266.